3b1t: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
<StructureSection load='3b1t' size='340' side='right'caption='[[3b1t]], [[Resolution|resolution]] 2.50Å' scene=''> | <StructureSection load='3b1t' size='340' side='right'caption='[[3b1t]], [[Resolution|resolution]] 2.50Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3b1t]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[3b1t]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3B1T OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3B1T FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=YCL:2-{[(2S)-1-AMINO-5-{[(1Z)-2-CHLOROETHANIMIDOYL]AMINO}-1-OXOPENTAN-2-YL]CARBAMOYL}BENZOIC+ACID'>YCL</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.5Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=YCL:2-{[(2S)-1-AMINO-5-{[(1Z)-2-CHLOROETHANIMIDOYL]AMINO}-1-OXOPENTAN-2-YL]CARBAMOYL}BENZOIC+ACID'>YCL</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3b1t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3b1t OCA], [https://pdbe.org/3b1t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3b1t RCSB], [https://www.ebi.ac.uk/pdbsum/3b1t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3b1t ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3b1t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3b1t OCA], [https://pdbe.org/3b1t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3b1t RCSB], [https://www.ebi.ac.uk/pdbsum/3b1t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3b1t ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
[https://www.uniprot.org/uniprot/PADI4_HUMAN PADI4_HUMAN] Genetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:[https://omim.org/entry/180300 180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Note=Could have an important role in the pathogenesis of rheumatoid arthritis by increasing citrullination of proteins in rheumatoid arthritis synovial tissues, leading, in a cytokine-rich milieu, to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context.<ref>PMID:12833157</ref> | |||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/PADI4_HUMAN PADI4_HUMAN] Catalyzes the citrullination/deimination of arginine residues of proteins. Citrullinates histone H3 at 'Arg-8' and/or 'Arg-17' and histone H4 at 'Arg-3', which prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.<ref>PMID:15339660</ref> <ref>PMID:15345777</ref> | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 27: | Line 25: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Causey CP]] | |||
[[Category: Causey | [[Category: Chumanevich AA]] | ||
[[Category: Chumanevich | [[Category: Ebrahimi P]] | ||
[[Category: Ebrahimi | [[Category: Hashimoto H]] | ||
[[Category: Hashimoto | [[Category: Hofseth LJ]] | ||
[[Category: Hofseth | [[Category: Jones JE]] | ||
[[Category: Jones | [[Category: Jones Jr LE]] | ||
[[Category: Jr | [[Category: Kamei D]] | ||
[[Category: Kamei | [[Category: Knuckley B]] | ||
[[Category: Knuckley | [[Category: Luo Y]] | ||
[[Category: Luo | [[Category: Sato M]] | ||
[[Category: Sato | [[Category: Shimizu T]] | ||
[[Category: Shimizu | [[Category: Slack JL]] | ||
[[Category: Slack | [[Category: Subramanian V]] | ||
[[Category: Subramanian | [[Category: Thompson PR]] | ||
[[Category: Thompson | |||